David Roder1, George W Zhao2, Sheetal Challam3, Alana Little2, Elisabeth Elder4, Gordana Kostadinovska5, Lisa Woodland6, David Currow7. 1. Cancer Information and Analysis, Cancer Institute New South Wales, Level 4, 1 Reserve Road, St Leonards NSW 2065, PO Box 41, Alexandria, NSW, 1435, Australia. david.roder@unisa.edu.au. 2. Cancer Information and Analysis, Cancer Institute New South Wales, Level 4, 1 Reserve Road, St Leonards NSW 2065, PO Box 41, Alexandria, NSW, 1435, Australia. 3. Equity, Multicultural Program, Cancer Institute New South Wales, St Leonards, NSW, Australia. 4. Specialist Breast Surgery, Westmead Breast Cancer Institute, Westmead, NSW, Australia. 5. Multicultural Health Service, Nepean Blue Mountains Local Health District, Penrith, NSW, Australia. 6. Priority Populations, South Eastern Sydney Local Health District, Sydney, NSW, Australia. 7. Cancer Institute New South Wales, St Leonards, NSW, Australia.
Abstract
BACKGROUND: NSW has a multicultural population with increasing migration from South East Asia, the Western Pacific and Eastern Mediterranean. OBJECTIVE: To compare cancer stage, treatment (first 12 months) and survival for 12 country of birth (COB) categories recorded on the population-based NSW Cancer Registry. DESIGN: Historic cohort study of invasive breast cancers diagnosed in 2003-2016. PATIENTS: Data for 48,909 women (18+ ages) analysed using linked cancer registry, hospital inpatient and Medicare and pharmaceutical benefits claims data. MEASUREMENT: Comparisons by COB using multivariate logistic regression and proportional hazards regression with follow-up of vital status to April 30th, 2020. RESULTS: Compared with the Australia-born, women born in China, the Philippines, Vietnam and Lebanon were younger at diagnosis, whereas those from the United Kingdom, Germany, Italy and Greece were older. Women born in China, the Philippines, Vietnam, Greece and Italy lived in less advantaged areas. Adjusted analyses indicated that: (1) stage at diagnosis was less localised for women born in Germany, Greece, Italy and Lebanon; (2) a lower proportion reported comorbidity for those born in China, the Philippines and Vietnam; (3) surgery type varied, with mastectomy more likely for women born in China, the Philippines and Vietnam, and less likely for women born in Italy, Greece and Lebanon; (4) radiotherapy was more likely where breast conserving surgery was more common (Greece, Italy, and Lebanon) and the United Kingdom; and (5) systemic drug therapy was less common for women born in China and Germany. Five-year survival in NSW was high by international standards and increasing. Adjusted analyses indicate that, compared with the Australian born, survival from death from cancer at 5 years from diagnosis was higher for women born in China, the Philippines, Vietnam, Italy, the United Kingdom and Greece. CONCLUSIONS: There is diversity by COB of stage, treatment and survival. Reasons for survival differences may include cultural factors and healthier migrant populations with lower comorbidity, and potentially, less complete death recording in Australia if some women return to their birth countries for treatment and end-of-life care. More research is needed to explore the cultural and clinical factors that health services need to accommodate.
BACKGROUND: NSW has a multicultural population with increasing migration from South East Asia, the Western Pacific and Eastern Mediterranean. OBJECTIVE: To compare cancer stage, treatment (first 12 months) and survival for 12 country of birth (COB) categories recorded on the population-based NSW Cancer Registry. DESIGN: Historic cohort study of invasive breast cancers diagnosed in 2003-2016. PATIENTS: Data for 48,909 women (18+ ages) analysed using linked cancer registry, hospital inpatient and Medicare and pharmaceutical benefits claims data. MEASUREMENT: Comparisons by COB using multivariate logistic regression and proportional hazards regression with follow-up of vital status to April 30th, 2020. RESULTS: Compared with the Australia-born, women born in China, the Philippines, Vietnam and Lebanon were younger at diagnosis, whereas those from the United Kingdom, Germany, Italy and Greece were older. Women born in China, the Philippines, Vietnam, Greece and Italy lived in less advantaged areas. Adjusted analyses indicated that: (1) stage at diagnosis was less localised for women born in Germany, Greece, Italy and Lebanon; (2) a lower proportion reported comorbidity for those born in China, the Philippines and Vietnam; (3) surgery type varied, with mastectomy more likely for women born in China, the Philippines and Vietnam, and less likely for women born in Italy, Greece and Lebanon; (4) radiotherapy was more likely where breast conserving surgery was more common (Greece, Italy, and Lebanon) and the United Kingdom; and (5) systemic drug therapy was less common for women born in China and Germany. Five-year survival in NSW was high by international standards and increasing. Adjusted analyses indicate that, compared with the Australian born, survival from death from cancer at 5 years from diagnosis was higher for women born in China, the Philippines, Vietnam, Italy, the United Kingdom and Greece. CONCLUSIONS: There is diversity by COB of stage, treatment and survival. Reasons for survival differences may include cultural factors and healthier migrant populations with lower comorbidity, and potentially, less complete death recording in Australia if some women return to their birth countries for treatment and end-of-life care. More research is needed to explore the cultural and clinical factors that health services need to accommodate.
Entities:
Keywords:
Birth countries; Breast cancer survival; New South Wales
Authors: Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman Journal: Lancet Date: 2018-01-31 Impact factor: 79.321
Authors: Stephanie H Lim; Geoff P Delaney; Joseph Descallar; Phan Sayaloune; George Papadatos; Paul de Souza Journal: PLoS One Date: 2014-04-21 Impact factor: 3.240
Authors: Hanna E Tervonen; Sanchia Aranda; David Roder; Hui You; Richard Walton; Stephen Morrell; Deborah Baker; David C Currow Journal: BMC Public Health Date: 2017-09-14 Impact factor: 3.295
Authors: Alana Little; David Roder; George W Zhao; Sheetal Challam; Ashanya Malalasekera; David Currow Journal: BMC Pulm Med Date: 2022-09-27 Impact factor: 3.320